2 results
Approved WMORecruiting
To investigate whether mifepristone (7-day, 1200 mg/day) added to treatment as usual (TAU), is more efficacious than placebo in reducing depressive symptom severity (Inventory of Depressive Symptoms-Self Rated questionnaire; IDS-SR) in patients with…
Approved WMORecruiting
The aim of this phase 2 study is to investigate the safety and efficacy of dazucorilant in the target ALS patient population.